Clinical Trial

Immune Defense Protein Impact On Respiratory Immune Outcomes

Recruiting

Record status

This record was last updated March 12, 2026 (before its estimated May 19, 2026 completion). Its status may not reflect the trial's current state.

Summary

The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability. This is conducted as a consumer-driven, decentralized observational clinical research study in adults aged 60 or older, using self-reported measures and questionnaires completed at home via the Chloe App.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-02-19.

Trial Details

NCT Number	NCT07431840
Lead Sponsor	Quantec Ltd Collaborators: People Science, Inc.
Conditions	Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
Enrollment	300 participants
Start Date	2025-12-05
Primary Completion	2026-05-19 (estimated)
Study Completion	2026-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-12